Latest News
All Times Eastern
- Work-life balance? Here’s how these small-business owners manage it.
- European gas futures jump as Chevron talks in Australia fail
- Will the ECB hike rates or not? Decision set to be cliff hanger as eurozone sentiment indicators deteriorate
- DocuSign shares rise after earnings, and other movers
- Barron's DocuSign, Apple, Smartsheet, Guidewire Software, RH, and More Stock Market Movers
- U.S. stock futures lean higher after difficult week on Wall Street
- Barron's Banks Are Stuck in a Rut. A Buyout Wave Could Be Building.
- Barron's High-Quality Dividend Stocks Are on Sale. Now Is the Time to Buy.
- Barron's Why Walt Disney Could Cave First in Its Cable Standoff With Charter
- Barron's 5 Federal Deficit Myths, Explained
to be replaced
CSL Ltd.
CSLAU
2.65
0.99%
Closed
$ 270.85
| Previous Close |
|---|
| $268.20 |
Volume: 671.5K
65 Day Avg: 929.61K
268.52
Day Range
271.00
255.87
52 Week Range
314.28
Partner Center
Your Watchlists
Recently Viewed Tickers
Overview
CSL Overview
Key Data
- Open $270.40
- Day Range 268.52 - 271.00
- 52 Week Range 255.87 - 314.28
- Market Cap $130.97B
- Shares Outstanding 482.93M
- Public Float 482.49M
- Beta 0.89
- Rev. per Employee $612.04K
- P/E Ratio 39.21
- EPS $6.91
- Yield 1.40%
- Dividend $1.62
- Ex-Dividend Date Mar 9, 2023
- Short Interest N/A
- % of Float Shorted N/A
- Average Volume 929.61K
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings 18
Full Ratings
Recent News
UniQure's shares fall on licensing deal for gene therapy
Shares of UniQure tumbled 17% in premarket trading on Thursday, the day after it announced that CSL Behring would acquire exclusive commercialization rights to its gene-therapy program. UniQure will receive a $450 millio...
Australia's CSL cuts outlook on tough competition
SYDNEY--CSL Ltd. (CSL.AU), Australia's largest pharmaceutical company, warned rising competition in the blood-plasma-therapies market will crimp its full-year earnings growth, after posting a small interim profit rise.
Australia's CSL considers bigger stock buyback
SYDNEY-- CSL Ltd., the world's second-biggest blood-products maker, said it would will consider another 950 million Australian dollar (US$880 million) buyback of its own shares after reporting a small rise in annual net pr...
Jarden Sticks to Its Buy Rating for CSL (CMXHF)
on TipRanks.com
UBS Reaffirms Their Buy Rating on CSL (CMXHF)
on TipRanks.com
Citi Sticks to Their Buy Rating for CSL (CMXHF)
on TipRanks.com
CSL (CMXHF) Receives a Hold from Goldman Sachs
on TipRanks.com
Jarden Reaffirms Their Buy Rating on CSL (CMXHF)
on TipRanks.com
CSL (CMXHF) Receives a Buy from Morgan Stanley
on TipRanks.com
J.P. Morgan Sticks to Their Buy Rating for CSL (CMXHF)
on TipRanks.com
Goldman Sachs Keeps Their Hold Rating on CSL (CMXHF)
on TipRanks.com
Morgan Stanley Reaffirms Their Buy Rating on CSL (CMXHF)
on TipRanks.com
UBS Remains a Buy on CSL (CMXHF)
on TipRanks.com
Jarden Sticks to Its Buy Rating for CSL (CMXHF)
on TipRanks.com
CSL Share Price: Is Now the Time to Grab More of This ASX Giant?
on TipRanks.com
UBS Reaffirms Their Buy Rating on CSL (CMXHF)
on TipRanks.com
Citi Sticks to Their Buy Rating for CSL (CMXHF)
on TipRanks.com
UBS Keeps Their Buy Rating on CSL (CMXHF)
on TipRanks.com
CSL (CMXHF) Gets a Buy from UBS
on TipRanks.com
3 ASX ETFs to Follow
on TipRanks.com
CSL (CMXHF) Receives a Buy from J.P. Morgan
on TipRanks.com
CSL (CMXHF) Receives a Buy from RBC Capital
on TipRanks.com
Two ASX Shares Backed by Analysts
on TipRanks.com
CSL Ltd.
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia.
Competitors
| Name | Chg % | Market Cap |
|---|---|---|
| Starpharma Holdings Ltd. | $63.63M | |
| Living Cell Technologies Ltd. | $22.9M |